Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), today announced that four of its abstracts have been accepted for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026. As one of the world's most influential gatherings in oncology, this year’s meeting will take place from April 17 to 22 at the San Diego Convention Center in San Diego, California.
Marking its fourth consecutive year of participation, Insilico will showcase a robust portfolio of four cutting-edge oncology programs, including two innovative projects originated from its UAE-based R&D center. In the meantime, we invite all partners and researchers to visit the Insilico team at Booth #1511 in the exhibit hall to explore our latest data and discuss potential collaborations. If you are interested in setting up a meeting with our team at the conference, please email: BD@insilico.com or visit our booth during the exhibit hall hours.
At AACR 2026, Insilico will unveil four novel cancer inhibitors discovered via its end-to-end Pharma.AI platform. By harnessing trillions of data points and millions of molecular fragments, the platform integrates generative biology for target discovery with generative chemistry for de novo molecular design, accelerating the path from data to drug candidates.
Abstract Title: ISM6166, a novel oral pan-KRAS (ON/OFF) inhibitor shows robust anti-tumor activity in solid tumors with KRAS alterations
https://www.abstractsonline.com/pp8/#!/21436/presentation/8812
Session category: Novel Antitumor Agents 1
Session title: Experimental and Molecular Therapeutics
Session date & time: April 19, 2026, 2:00 PM - 5:00 PM
Published abstract number: 425
Description: As one of the most prevalent cancer drivers, KRAS alterations occur in approximately 17% of all solid tumors, including pancreatic, colorectal, lung adenocarcinoma, and esophagogastric cancers. Despite recent advances, KRAS G12C–selective inhibitors binding specifically to its inactive conformation face clinical challenges in achieving durable therapeutic efficacy due to acquired drug resistance, while the mutational diversity of KRAS-driven cancers restricts their utility across patient populations, representing a significant unmet medical need. On the other hand, broader inhibition targeting all RAS proteins, including HRAS and NRAS, might raise potential toxicity risk, as the RAS family is essential in normal cells. ISM6166, an oral pan-KRAS (ON/OFF) inhibitor, selectively targets all major KRAS variants in both inactive and active conformations across multiple solid tumors while sparing HRAS and NRAS, achieving high efficacy in vivo against diverse KRAS variants with a good safety profile.
Abstract Title: Cbl-b inhibition with ISM3830, a novel AI-generated small molecule, restores innate and adaptive immunity and demonstrates antitumor activity against solid tumors in vitro and in vivo
https://www.abstractsonline.com/pp8/#!/21436/presentation/8818
Session category: Novel Antitumor Agents 2
Session title: Experimental and Molecular Therapeutics
Session date & time: April 21, 2026, 9:00 AM - 12:00 PM
Published abstract number: 4561
Description:
Cbl-b is an intracellular immune checkpoint downstream of both CD28 and CTLA-4 signaling that negatively regulates activation of T cells, NK cells, dendritic cells, and mast cells, representing a promising, distinct target for cancer immunotherapy. ISM3830, a novel Cbl-b inhibitor, demonstrates strong Cbl-b inhibition in vitro and in vivo, leading to enhanced activation of primary human T cells and NK cells, restored function of suppressed T cells, and increased tumor infiltration and antitumor activity of T and NK cells.
Abstract Title: ISM6210, a potent and selective AI-discovered CDK4 inhibitor for the treatment of HR+/HER2- breast cancer
https://www.abstractsonline.com/pp8/#!/21436/presentation/8819
Session category: Novel Antitumor Agents 2
Session title: Experimental and Molecular Therapeutics
Session date & time: April 21, 2026, 9:00 AM - 12:00 PM
Published abstract number: 4562
Description: CDK4/6 kinases drive the G1-S cell cycle transition, and overactive cyclin–CDK4/6 complexes are common across cancer types. While clinically approved CDK4/6 inhibitors have benefited patients with HR+/HER2- breast cancer, their efficacy is constrained by dose-limiting hematological toxicities, particularly CDK6-driven myelosuppression. Hematopoietic stem cell activation relies primarily on CDK6, but breast cancer cells are more dependent on CDK4, suggesting a potential therapeutic window for a CDK4-selective inhibitor. ISM6210 is a potent, orally bioavailable CDK4 inhibitor with high selectivity over CDK6. With robust in vitro and in vivo efficacy alongside a promising hematologic safety margin, it represents a compelling therapeutic candidate for HR+/HER2- breast cancer treatment.
Abstract Title: ISM1745, an MTA-cooperative PRMT5 inhibitor discovered with generative AI for the treatment of MTAP-deleted cancer
https://www.abstractsonline.com/pp8/#!/21436/presentation/8696
Session category: Epigenetic Modulators 2
Session title: Experimental and Molecular Therapeutics
Session date & time: April 22, 2026, 9:00 AM - 12:00 PM
Published abstract number:7077
Description: MTAP deficiency is observed in approximately 15% of human cancers and leads to accumulation of methylthioadenosine (MTA), which competes with the methyl-donor S-adenosylmethionine (SAM) to partially inhibit post-translational methyltransferase activity of PRMT5. ISM1745 is a potent and selective MTA-cooperative PRMT5 inhibitor, targeting MTAP-deficient but not MTAP-wild type cells, leading to robust anti-tumor efficacy. Strong antitumor activity as a monotherapy and synergistically in combination with MAT2A inhibition positions ISM1745 as a promising potential therapy for treatment of MTAP-deleted cancers.
Harnessing state-of-the-art AI and automation technologies, Insilico has significantly improved the efficiency of preclinical drug development, setting a benchmark for AI-driven drug R&D. While traditional early-stage drug discovery typically requires an average of 4.5 years, Insilico has nominated 20 preclinical candidates from 2021 to 2024, with an average timeline—from project initiation to preclinical candidate (PCC) nomination—of just 12 to 18 months per program, with only 60 to 200 molecules synthesized and tested in each program.
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com